ORIC-533

• Description :

  ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment[1].

• UNSPSC :

  12352005

• Target :

  CD73

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/oric-533.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O[C@H]1[C@@H](O)[C@H](N2C3=NC(Cl)=NC(NC4CCCC4)=C3C=N2)O[C@@H]1CO[C@](P(O)(O)=O)(CO)COCC5=NN=NN5

• Molecular Formula :

  C20H29ClN9O9P

• Molecular Weight :

  605.93

• References & Citations :

  [1]Junttila M R, et al., ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma[J]. Cancer Research, 2022, 82 (12_Supplement) : 2074-2074.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [2641306-62-7]